Trajan Scientific and Medical

media@trajanscimed.com
www.trajanscimed.com

FOR IMMEDIATE RELEASE

Trajan invests in personalised therapeutic technologies centre

Melbourne, Victoria, Australia – 20 November 2018

Trajan Scientific and Medical (Trajan) is pleased to be part of launching the ARC Centre for Personalised Therapeutics Technologies (ARC CPTT) today in Melbourne, Australia. The centre aims to provide a world-leading commercial advantage in developing therapeutic treatments.

Headquartered at the Department of Pharmacology and Therapeutics at the University of Melbourne, the centre brings together the University of Melbourne, Monash University, University of Western Australia, and 17 partner organisations in government and industry.

ARC CPTT is training a new generation of enterprising biomedical researchers. It aims to transform the medical technologies and pharmaceutical (MTP) industry's access to emergent technologies that enable accelerated translation of discoveries into benefits for end users.

Mr Stephen Tomisich, CEO, chair and founder of Trajan Scientific and Medical, said that ARC CPTT's research in mechanistic, diagnostic, and therapeutic precision medicine complements Trajan's strategic direction to improve human wellbeing through analytical measurements - which play an increasingly important role in producing meaningful and reliable data to inform healthcare.

Trajan's success is built on developing and commercialising technologies, with a long history of collaboration with academic and industry partners.

"We strongly believe in our collaboration model to drive innovation and proliferation of technologies; so investing in ARC CPTT is another embodiment of our approach." said Mr Tomisich.

"Being an Australian-based manufacturer and exporter on the global stage, we see our role as not only be an active industry participant supporting early career researchers; but also a device manufacturing and commercialisation partner with other participants," he said.

Trajan is also the sole industry founder another ARC Industrial Transformation Training Centre, ASTech, ARC Training Centre for Portable Analytical Separation Technologies. Since its establishment in 2013 with academic founder University of Tasmania; ASTech has expanded to include the University of South Australia in 2016, and La Trobe University in 2017, and continues to provide industry experience within Trajan and its partners.

Trajan has seen the benefit of student participation bringing fresh perspective and talent, while industry engagement brings expertise, guidance and visibility on emerging trends in the scientific and clinical community.

"We have many R&D and commercialisation programs underway, but an exciting example which began with ASTech, is the commercial release of first-generation hemaPEN® microsampling technology this year." he said.

hemaPEN provides a minimally invasive and convenient sampling procedure for collecting four identical dried blood spot (DBS) based samples.* The proposed concept of the hemaPEN platform technology was developed in 2015 by ASTech, with the commercialisation pathway realised by Trajan.

“With ARC CPTT, we hope to promote the same collaborative and commercial success in the medtech and pharmaceutical (MTP) sector that we have been nurturing in analytical science.” he said.

ARC CPTT partners

Downloads

Press release - International [PDF]
Press release - Australia [PDF]
Flyer - ARC CPTT [PDF]

More information

therapeutics-technologies.com.au
www.unimelb.edu.au
www.trajanscimed.com

Related news

University awarded $10.5 million ARC grants for innovative training centres

Media contact information
Trajan Scientific and Medical
Tel: +44 (0) 1244 403 100
media@trajanscimed.com

**The hemaPEN is under development and the prototype device is supplied for research or investigational purposes only. This device is not for therapeutic or diagnostic use. For more information, visit www.hemapen.com.*

PR-0047-G_Aus

NOTES FOR EDITORS

1. Trajan Scientific and Medical

Trajan is focused on breakthrough solutions to improve human wellbeing through biological, environmental or food related measurements. Our focus is on developing and commercialising technologies that enable analytical systems to be more selective, sensitive and specific - especially those that can lead to portability, miniaturisation and affordability.

A 17,000 m^2 Ringwood site in Melbourne, Victoria, is home to Trajan's corporate headquarters and ISO accredited manufacturing operations. With over 400 staff worldwide across Australia, Europe, USA and Asia, Trajan serves customers in over 100 countries with highly specialised consumables and components used in scientific analysis and clinical applications.

www.trajanscimed.com

2. ARC Centre for Personalised Therapeutics Technologies

The ARC Centre for Personalised Therapeutics Technologies (ARC CPTT) is an Industrial Transformation Training Centre comprising a multidisciplinary collaboration between academic researchers and industry partners.

The Centre aims to advance and deploy new technologies that will remove long-standing barriers to drug discovery and development, while training early career researchers to transform the way the Medical Technology and Pharmaceutical (MTP) industry accesses these emergent technologies.

ARC CPTT is funded by the Australian Government through the Australian Research Council Industrial Transformation Research Program.

therapeutics-technologies.com.au